{"hands_on_practices": [{"introduction": "A core competency in psychedelic-assisted psychotherapy is the ability to navigate complex and sometimes concerning post-session presentations. It is crucial to distinguish between the expected, transient sequelae of a profound experience and the emergence of a separate, serious psychiatric condition. This problem, [@problem_id:4744165], challenges you to apply principles of differential diagnosis to a scenario involving new-onset psychosis following a psilocybin session, weighing factors like the clinical timeline, symptom phenomenology, and patient history to arrive at the safest and most appropriate management decision.", "problem": "A $29$-year-old man with treatment-resistant major depressive disorder is enrolled in a psilocybin-assisted psychotherapy protocol at an academic center. Screening prior to enrollment documents no personal history of psychotic or bipolar disorders; however, his father developed schizophrenia in his early $20$s. He tapered off selective serotonin reuptake inhibitor medication $6$ weeks prior per protocol. During his second dosing session, he receives oral psilocybin $25$ mg under continuous monitoring by two trained facilitators. About $40$ minutes after ingestion, he experiences intense visual distortions, synesthesia, and transient ego-dissolution with alternating waves of anxiety and awe. He remains oriented to person, place, and time throughout the session, can be verbally redirected, and acknowledges that what he is perceiving is drug-related. Vital signs during the peak include blood pressure $148/92$ mmHg, heart rate $110$ beats per minute, respiratory rate $18$ breaths per minute, and temperature $37.1$ °C. There is no muscle rigidity or clonus. By $5$ hours post ingestion, his perception normalizes, he has intact insight, and he participates in an integrative debrief.\n\nAt $72$ hours post session, he returns reporting persistent ideas of reference (believing neutral events subtly refer to him), new-onset auditory hallucinations commenting on his actions, and a marked decline in functioning with reduced work performance and social withdrawal. He has had poor sleep for $2$ nights, feels fearful rather than euphoric, and is difficult to redirect. On exam, he is oriented, but shows thought disorganization, blunted affect, and limited insight. He denies recent substance use; urine toxicology is negative. Collateral from his partner indicates that subtle social withdrawal and suspiciousness had begun over the past $4$ weeks, predating the psilocybin session. There are no tremors, hyperreflexia, diaphoresis, or hyperthermia. The clinical team must decide whether this represents transient drug-related phenomena versus an emergent psychotic disorder and select an immediate management strategy.\n\nUsing core definitions from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and well-tested facts about classic psychedelic pharmacology and time course (psilocybin’s active metabolite psilocin has a half-life on the order of $\\sim 3$ hours; acute subjective effects typically resolve within $\\sim 4$–$6$ hours), which of the following is the most appropriate next-step management?\n\nA. Reassure that this is a typical integration phase of hallucinogen intoxication; continue with the next psilocybin session as scheduled and avoid medications to preserve therapeutic content.\n\nB. Provide a low-stimulus environment and administer lorazepam $1$–$2$ mg as needed for anxiety; defer antipsychotics and schedule routine follow-up in $1$ week.\n\nC. Diagnose hallucinogen persisting perception disorder and initiate clonazepam $0.5$–$1$ mg nightly while continuing the psilocybin protocol, since visual phenomena are expected to evolve into auditory experiences.\n\nD. Treat as an emergent psychotic disorder likely unmasked by psilocybin exposure: discontinue further psychedelic sessions, perform a safety assessment (including risk of harm to self or others), initiate an antipsychotic (e.g., risperidone), and coordinate urgent referral to early intervention in psychosis services.\n\nE. Suspect serotonin toxicity from $5$-hydroxytryptamine $2\\mathrm{A}$ receptor agonism; administer cyproheptadine and admit for medical management of a serotonergic crisis.", "solution": "The clinical presentation described is highly suggestive of a primary psychotic disorder, not a transient or expected effect of psilocybin. The correct answer is D because it prioritizes safety and addresses the most likely diagnosis. Here's a breakdown of the options:\n\n*   **A. Reassure that this is a typical integration phase...**: Incorrect. The symptoms—persistent ideas of reference, auditory hallucinations commenting on the patient's actions, and thought disorganization—are not typical integration phenomena. They are hallmark features of psychosis. Continuing with the protocol would be contraindicated and potentially harmful.\n*   **B. Provide a low-stimulus environment and administer lorazepam...**: Insufficient. While a low-stimulus environment and anxiolytics might manage acute agitation, they do not address the underlying psychotic process. Deferring antipsychotic treatment is inappropriate given the severity of symptoms and the risk of clinical deterioration.\n*   **C. Diagnose hallucinogen persisting perception disorder (HPPD)...**: Incorrect. HPPD is characterized by persistent perceptual disturbances (e.g., visual snow, geometric patterns, trails) following hallucinogen use. The patient's primary symptoms are in the domains of thought content and process (delusions, formal thought disorder) and auditory perception, which are not characteristic of HPPD.\n*   **D. Treat as an emergent psychotic disorder...**: Correct. This is the most clinically sound and responsible course of action. The patient's symptoms, decline in functioning, and limited insight, especially in the context of a strong family history of schizophrenia and subtle prodromal signs, point toward an emerging primary psychotic disorder (e.g., schizophreniform disorder). Psilocybin likely acted as a precipitant or accelerator. The immediate priorities are ensuring safety, initiating antipsychotic medication, and referring to specialized care for early psychosis.\n*   **E. Suspect serotonin toxicity...**: Incorrect. Serotonin toxicity is a medical emergency characterized by a triad of autonomic instability (e.g., hyperthermia, tachycardia, labile blood pressure), neuromuscular hyperactivity (e.g., clonus, hyperreflexia, tremor), and altered mental status. The patient does not exhibit the key neuromuscular or autonomic features of this syndrome.", "answer": "$$\\boxed{D}$$", "id": "4744165"}, {"introduction": "The therapeutic and physiological effects of a psychedelic are intrinsically linked to its concentration in the body over time. A solid grasp of pharmacokinetic principles is therefore essential for safe and effective session design, allowing clinicians to anticipate the onset, peak, and duration of a drug's action. This exercise, [@problem_id:4744362], guides you through the fundamental process of deriving and applying a one-compartment model to predict the peak plasma concentration of MDMA, a skill that translates directly to optimizing the therapeutic window and ensuring patient safety.", "problem": "A clinical pharmacokinetic question arises in the context of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), where precise timing and magnitude of peak plasma concentration are relevant to session planning and safety monitoring. Consider a single oral dose administered at time $t=0$ in a patient for whom MDMA disposition over the therapeutic range is well approximated by a one-compartment model with first-order absorption and first-order elimination and no absorption lag. Let $A_{g}(t)$ denote the amount of drug in the gastrointestinal tract and $A_{c}(t)$ the amount in the central compartment. The apparent volume of distribution is $V$, oral bioavailability is $F$, the absorption rate constant is $k_{a}$, and the elimination rate constant is $k_{e}$. Assume linearity and that the initial conditions are $A_{g}(0)=D$ and $A_{c}(0)=0$ for an oral dose $D$.\n\nStarting from mass-balance and first-order kinetics, derive the expression for the plasma concentration $C(t)$ in the central compartment as a function of time $t$. Then, using calculus, determine the time of maximum concentration $t_{\\max}$ and the corresponding peak concentration $C_{\\max}$, expressed in terms of the model parameters. Identify the minimal set of parameter values required to compute $C_{\\max}$ under this model.\n\nFinally, compute the numerical value of $C_{\\max}$ for the following scientifically plausible parameterization relevant to a $70\\,\\mathrm{kg}$ adult: $F=0.70$, $D=100\\,\\mathrm{mg}$, $V=3.5\\,\\mathrm{L/kg}\\times 70\\,\\mathrm{kg}=245\\,\\mathrm{L}$, $k_{a}=1.0\\,\\mathrm{h}^{-1}$, and $k_{e}=0.10\\,\\mathrm{h}^{-1}$. Round your answer to four significant figures. Express the concentration in $\\mathrm{mg/L}$.", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, objective, and complete. It describes a standard one-compartment pharmacokinetic model with first-order absorption and elimination, which is a fundamental concept in pharmacology. All parameters are clearly defined, and the objectives are specific and solvable using standard mathematical methods. The problem is therefore deemed valid.\n\nThe solution is developed in four parts: derivation of the plasma concentration function $C(t)$, determination of the time to maximum concentration $t_{\\max}$ and the peak concentration $C_{\\max}$, identification of the minimal parameter set, and numerical computation of $C_{\\max}$ for the given parameters.\n\nFirst, we establish the system of differential equations based on mass-balance principles for a one-compartment model. Let $A_{g}(t)$ be the amount of drug in the gastrointestinal (GI) tract and $A_{c}(t)$ be the amount in the central compartment (representing plasma and well-perfused tissues) at time $t$.\n\nThe rate of decrease of the drug in the GI tract is governed by first-order absorption with rate constant $k_a$:\n$$ \\frac{dA_g(t)}{dt} = -k_a A_g(t) $$\nThe initial condition is that the entire dose $D$ is in the GI tract at $t=0$, so $A_g(0) = D$. This is a first-order linear ordinary differential equation. Separation of variables and integration yields:\n$$ \\int_{A_g(0)}^{A_g(t)} \\frac{dA_g}{A_g} = \\int_{0}^{t} -k_a d\\tau $$\n$$ \\ln\\left(\\frac{A_g(t)}{A_g(0)}\\right) = -k_a t $$\n$$ A_g(t) = D \\exp(-k_a t) $$\n\nThe rate of change of the amount of drug in the central compartment is the difference between the rate of drug absorption from the GI tract and the rate of drug elimination from the central compartment. The rate of absorption into the central compartment is $F k_a A_g(t)$, where $F$ is the bioavailability. The rate of elimination is first-order with rate constant $k_e$, given by $k_e A_c(t)$. Thus, the differential equation for $A_c(t)$ is:\n$$ \\frac{dA_c(t)}{dt} = F k_a A_g(t) - k_e A_c(t) $$\nSubstituting the expression for $A_g(t)$:\n$$ \\frac{dA_c(t)}{dt} = F k_a D \\exp(-k_a t) - k_e A_c(t) $$\nRearranging gives a first-order linear non-homogeneous differential equation:\n$$ \\frac{dA_c(t)}{dt} + k_e A_c(t) = F k_a D \\exp(-k_a t) $$\nThis equation can be solved using an integrating factor, $\\mu(t) = \\exp(\\int k_e dt) = \\exp(k_e t)$. Multiplying the equation by $\\mu(t)$:\n$$ \\exp(k_e t) \\frac{dA_c(t)}{dt} + k_e \\exp(k_e t) A_c(t) = F k_a D \\exp(-k_a t) \\exp(k_e t) $$\nThe left side is the derivative of the product $A_c(t)\\exp(k_e t)$:\n$$ \\frac{d}{dt}\\left(A_c(t) \\exp(k_e t)\\right) = F k_a D \\exp((k_e - k_a) t) $$\nIntegrating both sides with respect to time from $0$ to $t$, and assuming $k_a \\neq k_e$:\n$$ \\int_{0}^{t} \\frac{d}{d\\tau}\\left(A_c(\\tau) \\exp(k_e \\tau)\\right) d\\tau = \\int_{0}^{t} F k_a D \\exp((k_e - k_a) \\tau) d\\tau $$\n$$ A_c(t)\\exp(k_e t) - A_c(0)\\exp(0) = F k_a D \\left[ \\frac{\\exp((k_e - k_a) \\tau)}{k_e - k_a} \\right]_0^t $$\nUsing the initial condition $A_c(0)=0$:\n$$ A_c(t)\\exp(k_e t) = \\frac{F k_a D}{k_e - k_a} (\\exp((k_e - k_a) t) - 1) $$\nSolving for $A_c(t)$:\n$$ A_c(t) = \\frac{F k_a D}{k_e - k_a} (\\exp(-k_a t) - \\exp(-k_e t)) $$\nIt is conventional to write this with a positive denominator, so we multiply the numerator and denominator by $-1$:\n$$ A_c(t) = \\frac{F k_a D}{k_a - k_e} (\\exp(-k_e t) - \\exp(-k_a t)) $$\nThe plasma concentration $C(t)$ is the amount of drug in the central compartment divided by the apparent volume of distribution $V$:\n$$ C(t) = \\frac{A_c(t)}{V} = \\frac{F D k_a}{V(k_a - k_e)} (\\exp(-k_e t) - \\exp(-k_a t)) $$\n\nNext, to find the time of maximum concentration, $t_{\\max}$, we find the time at which the rate of change of concentration is zero. We differentiate $C(t)$ with respect to $t$ and set the derivative to $0$.\n$$ \\frac{dC(t)}{dt} = \\frac{F D k_a}{V(k_a - k_e)} \\frac{d}{dt}(\\exp(-k_e t) - \\exp(-k_a t)) $$\n$$ \\frac{dC(t)}{dt} = \\frac{F D k_a}{V(k_a - k_e)} (-k_e \\exp(-k_e t) + k_a \\exp(-k_a t)) $$\nSetting $\\frac{dC(t)}{dt} = 0$ at $t = t_{\\max}$:\n$$ -k_e \\exp(-k_e t_{\\max}) + k_a \\exp(-k_a t_{\\max}) = 0 $$\n$$ k_a \\exp(-k_a t_{\\max}) = k_e \\exp(-k_e t_{\\max}) $$\nSolving for $t_{\\max}$:\n$$ \\frac{k_a}{k_e} = \\frac{\\exp(-k_e t_{\\max})}{\\exp(-k_a t_{\\max})} = \\exp((k_a - k_e)t_{\\max}) $$\nTaking the natural logarithm of both sides:\n$$ \\ln\\left(\\frac{k_a}{k_e}\\right) = (k_a - k_e)t_{\\max} $$\n$$ t_{\\max} = \\frac{\\ln(k_a/k_e)}{k_a - k_e} = \\frac{\\ln(k_a) - \\ln(k_e)}{k_a - k_e} $$\n\nTo find the maximum concentration, $C_{\\max}$, we substitute $t_{\\max}$ into the expression for $C(t)$.\n$$ C_{\\max} = C(t_{\\max}) = \\frac{F D k_a}{V(k_a - k_e)} (\\exp(-k_e t_{\\max}) - \\exp(-k_a t_{\\max})) $$\nFrom the condition for $t_{\\max}$, we have $\\exp(-k_a t_{\\max}) = \\frac{k_e}{k_a}\\exp(-k_e t_{\\max})$. Substituting this into the expression for $C_{\\max}$:\n$$ C_{\\max} = \\frac{F D k_a}{V(k_a - k_e)} \\left(\\exp(-k_e t_{\\max}) - \\frac{k_e}{k_a}\\exp(-k_e t_{\\max})\\right) $$\n$$ C_{\\max} = \\frac{F D k_a}{V(k_a - k_e)} \\exp(-k_e t_{\\max}) \\left(1 - \\frac{k_e}{k_a}\\right) $$\n$$ C_{\\max} = \\frac{F D k_a}{V(k_a - k_e)} \\exp(-k_e t_{\\max}) \\left(\\frac{k_a - k_e}{k_a}\\right) $$\nSimplifying by canceling terms $(k_a - k_e)$ and $k_a$:\n$$ C_{\\max} = \\frac{F D}{V} \\exp(-k_e t_{\\max}) $$\nSubstituting the expression for $t_{\\max}$:\n$$ C_{\\max} = \\frac{F D}{V} \\exp\\left(-k_e \\frac{\\ln(k_a/k_e)}{k_a - k_e}\\right) $$\n\nThe minimal set of parameter values required to compute $C_{\\max}$ under this model, as seen from the final expression, consists of the individual parameters that define the system: the oral bioavailability $F$, the dose $D$, the apparent volume of distribution $V$, the absorption rate constant $k_a$, and the elimination rate constant $k_e$.\n\nFinally, we compute the numerical value of $C_{\\max}$ for the provided parameters:\n$F=0.70$ (dimensionless)\n$D=100\\,\\mathrm{mg}$\n$V=245\\,\\mathrm{L}$\n$k_{a}=1.0\\,\\mathrm{h}^{-1}$\n$k_{e}=0.10\\,\\mathrm{h}^{-1}$\n\nFirst, calculate $t_{\\max}$:\n$$ t_{\\max} = \\frac{\\ln(1.0/0.10)}{1.0 - 0.10} = \\frac{\\ln(10)}{0.9} \\,\\mathrm{h} $$\nNow, calculate $C_{\\max}$:\n$$ C_{\\max} = \\frac{F D}{V} \\exp(-k_e t_{\\max}) = \\frac{0.70 \\times 100\\,\\mathrm{mg}}{245\\,\\mathrm{L}} \\exp\\left(-0.10 \\times \\frac{\\ln(10)}{0.9}\\right) $$\n$$ C_{\\max} = \\frac{70}{245} \\exp\\left(-\\frac{0.10}{0.90} \\ln(10)\\right) \\,\\mathrm{mg/L} $$\n$$ C_{\\max} = \\frac{2}{7} \\exp\\left(-\\frac{1}{9} \\ln(10)\\right) \\,\\mathrm{mg/L} $$\nUsing the property of logarithms, $\\exp(a \\ln b) = b^a$:\n$$ C_{\\max} = \\frac{2}{7} \\cdot 10^{-1/9} \\,\\mathrm{mg/L} $$\nNumerically evaluating this expression:\n$10^{-1/9} \\approx 0.77426368$\n$\\frac{2}{7} \\approx 0.28571428$\n$$ C_{\\max} \\approx 0.28571428 \\times 0.77426368 \\approx 0.22121819 \\,\\mathrm{mg/L} $$\nRounding to four significant figures, we get $0.2212\\,\\mathrm{mg/L}$.", "answer": "$$\\boxed{0.2212}$$", "id": "4744362"}, {"introduction": "Beyond asking *if* a therapy works, rigorous science seeks to understand *how* it works. In psychedelic research, a central hypothesis is that the drug's therapeutic benefits are mediated by the subjective quality of the experience it induces. This exercise, [@problem_id:4744347], introduces you to mediation analysis, the statistical tool used to formally test such hypotheses. By calculating an indirect effect, you will practice the quantitative reasoning that underpins our understanding of how a psychedelic dose might translate into clinical improvement via a psychological mechanism like the mystical experience.", "problem": "A randomized controlled trial (RCT) of psilocybin-assisted psychotherapy examined whether acute dosing intensity, measured as psilocybin dose in $\\text{mg}/\\text{kg}$, influences subsequent symptom improvement via subjective mystical-type experience. Investigators modeled a single-mediator pathway in which dose predicts Mystical Experience Questionnaire (MEQ) total score, and MEQ score predicts post-treatment symptom change (defined as baseline severity minus follow-up severity, so that positive values indicate improvement), controlling for baseline severity and therapist effects in both regressions. Let $D$ denote dose ($\\text{mg}/\\text{kg}$), $M$ denote MEQ total score, and $Y$ denote symptom change in points on a validated depression scale.\n\nFrom ordinary least squares fits in a sample of $n = 120$ participants, the following path estimates and their standard errors were obtained:\n- The $D \\rightarrow M$ path estimate: $\\hat{\\alpha} = 180$ and $SE(\\hat{\\alpha}) = 20$.\n- The $M \\rightarrow Y$ path estimate (controlling for $D$): $\\hat{\\beta} = 0.12$ and $SE(\\hat{\\beta}) = 0.03$.\nAssume $\\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}) \\approx 0$.\n\nUsing the simple single-mediator framework and the product-of-paths approach, compute the estimated indirect effect of dose on symptom change operating through MEQ. Express your final numerical answer in the unit “symptom-change points per $\\text{mg}/\\text{kg}$,” and round your final answer to four significant figures.\n\nSeparately, briefly describe in words the criteria that would be used to judge the statistical significance of this indirect effect under (i) a nonparametric bootstrap approach and (ii) a large-sample normal-theory approximation. You should not perform any additional computations beyond the requested indirect effect; provide only the conceptual criteria for significance.", "solution": "The problem requires the calculation of an indirect effect in a single-mediator model and a description of the criteria for assessing its statistical significance using two different methods. The problem is well-posed and scientifically grounded in the field of biostatistics and psychiatric research.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n- Model: Single-mediator pathway $D \\rightarrow M \\rightarrow Y$.\n- Variables:\n  - $D$: Dose in $\\text{mg}/\\text{kg}$.\n  - $M$: Mystical Experience Questionnaire (MEQ) total score.\n  - $Y$: Symptom change (positive values indicate improvement).\n- Sample Size: $n = 120$.\n- Path Estimates from Ordinary Least Squares (OLS):\n  - $D \\rightarrow M$ path estimate: $\\hat{\\alpha} = 180$.\n  - Standard error of $\\hat{\\alpha}$: $SE(\\hat{\\alpha}) = 20$.\n  - $M \\rightarrow Y$ path estimate (controlling for $D$): $\\hat{\\beta} = 0.12$.\n  - Standard error of $\\hat{\\beta}$: $SE(\\hat{\\beta}) = 0.03$.\n- Covariance Assumption: $\\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}) \\approx 0$.\n- Tasks:\n  1. Compute the estimated indirect effect using the product-of-paths approach.\n  2. Round the numerical answer to four significant figures.\n  3. Describe the criteria for statistical significance under (i) a nonparametric bootstrap approach and (ii) a large-sample normal-theory approximation.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is valid. It describes a standard mediation analysis, which is a formal statistical procedure. All necessary data for the calculation ($\\hat{\\alpha}$, $\\hat{\\beta}$) are provided. The model is clearly defined, and the tasks are specific and answerable. The context is scientifically current and realistic. The problem adheres to all criteria for a valid scientific question.\n\n**Step 3: Verdict and Action**\nThe problem is valid and can be solved as stated.\n\n**Solution: Calculation of the Indirect Effect**\n\nThe mediation model proposed is $D \\rightarrow M \\rightarrow Y$, where $D$ is the independent variable (dose), $M$ is the mediator (MEQ score), and $Y$ is the dependent variable (symptom change). The model involves two regression equations:\n1. $M = c_M + \\alpha D + \\text{covariates}_M + \\epsilon_M$\n2. $Y = c_Y + \\beta M + \\gamma' D + \\text{covariates}_Y + \\epsilon_Y$\n\nHere, $\\alpha$ represents the effect of $D$ on $M$, and $\\beta$ represents the effect of $M$ on $Y$ after controlling for the direct effect of $D$ (represented by $\\gamma'$).\n\nThe indirect effect of $D$ on $Y$ through the mediator $M$ is defined as the product of the two path coefficients, $\\alpha \\beta$. This product quantifies how much the outcome $Y$ is expected to change for a one-unit change in the predictor $D$, as transmitted through the mediator $M$.\n\nWe are given the ordinary least squares estimates for these path coefficients:\n- $\\hat{\\alpha} = 180$\n- $\\hat{\\beta} = 0.12$\n\nThe estimated indirect effect is the product of these estimates:\n$$ \\text{Indirect Effect} = \\hat{\\alpha} \\hat{\\beta} $$\nSubstituting the given values:\n$$ \\text{Indirect Effect} = 180 \\times 0.12 = 21.6 $$\nThe units of this effect are the product of the units of $\\hat{\\alpha}$ and $\\hat{\\beta}$. The units of $\\hat{\\alpha}$ are (units of $M$) per (unit of $D$), or $\\text{MEQ points per mg/kg}$. The units of $\\hat{\\beta}$ are (units of $Y$) per (unit of $M$), or $\\text{symptom-change points per MEQ point}$. The product has units:\n$$ \\left( \\frac{\\text{MEQ points}}{\\text{mg/kg}} \\right) \\times \\left( \\frac{\\text{symptom-change points}}{\\text{MEQ point}} \\right) = \\frac{\\text{symptom-change points}}{\\text{mg/kg}} $$\nThis matches the requested unit. The problem requires the answer to be rounded to four significant figures. The calculated value $21.6$ has three significant figures. To express it with four, we add a trailing zero: $21.60$.\n\n**Solution: Criteria for Statistical Significance**\n\nThe problem asks for a conceptual description of the criteria for judging the statistical significance of this indirect effect, $\\hat{\\alpha}\\hat{\\beta}$.\n\n**(i) Nonparametric Bootstrap Approach**\nThe nonparametric bootstrap is a computational resampling method used to estimate the sampling distribution of a statistic without making strong distributional assumptions.\n1.  A large number of bootstrap samples, say $B$ (e.g., $B=5000$ or $B=10000$), are generated by sampling with replacement from the original dataset of $n=120$ participants. Each bootstrap sample also has a size of $n=120$.\n2.  For each bootstrap sample $b$ (from $1$ to $B$), the two regression models are re-fitted to obtain bootstrap estimates of the path coefficients, $\\hat{\\alpha}^*_b$ and $\\hat{\\beta}^*_b$.\n3.  The indirect effect is computed for each bootstrap sample: $(\\hat{\\alpha}\\hat{\\beta})^*_b = \\hat{\\alpha}^*_b \\hat{\\beta}^*_b$. This process results in a bootstrap distribution of $B$ indirect effect estimates.\n4.  **Criterion for Significance**: A confidence interval (CI) for the indirect effect is constructed from this bootstrap distribution. A common choice is a $95\\%$ percentile CI, which is defined by the $2.5^{th}$ and $97.5^{th}$ percentiles of the ordered bootstrap estimates. The indirect effect is deemed statistically significant at the $\\alpha_{level} = 0.05$ if this $95\\%$ CI does **not** contain the value $0$. An interval that is entirely positive (e.g., $[12.5, 30.7]$) or entirely negative implies a significant effect.\n\n**(ii) Large-Sample Normal-Theory Approximation (Sobel Test)**\nThis method relies on the aymptotic normality of the product term $\\hat{\\alpha}\\hat{\\beta}$. It uses the delta method to derive an approximate standard error for the indirect effect.\n1.  The test statistic is a $Z$-score, calculated as the estimated indirect effect divided by its standard error:\n    $$ Z = \\frac{\\hat{\\alpha}\\hat{\\beta}}{SE(\\hat{\\alpha}\\hat{\\beta})} $$\n2.  The standard error, $SE(\\hat{\\alpha}\\hat{\\beta})$, is approximated by the first-order Taylor series expansion (the delta method). The general formula is:\n    $$ SE(\\hat{\\alpha}\\hat{\\beta}) \\approx \\sqrt{\\hat{\\alpha}^2 [SE(\\hat{\\beta})]^2 + \\hat{\\beta}^2 [SE(\\hat{\\alpha})]^2 + 2\\hat{\\alpha}\\hat{\\beta}\\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta})} $$\n    Given the simplifying assumption that $\\operatorname{Cov}(\\hat{\\alpha}, \\hat{\\beta}) \\approx 0$, this reduces to:\n    $$ SE(\\hat{\\alpha}\\hat{\\beta}) \\approx \\sqrt{\\hat{\\alpha}^2 [SE(\\hat{\\beta})]^2 + \\hat{\\beta}^2 [SE(\\hat{\\alpha})]^2} $$\n3.  **Criterion for Significance**: The calculated $Z$ statistic is compared to critical values from the standard normal distribution $\\mathcal{N}(0,1)$. For a two-tailed test with a significance level of $\\alpha_{level} = 0.05$, the critical value is approximately $1.96$. The indirect effect is deemed statistically significant if the absolute value of the $Z$ statistic exceeds this critical value, i.e., $|Z| > 1.96$. Equivalently, the $p$-value, calculated as $2 \\times P(Z' > |Z|)$ where $Z' \\sim \\mathcal{N}(0,1)$, must be less than $\\alpha_{level}$.\nIt is noteworthy that this normal-theory approximation performs poorly in small samples because the distribution of a product of two coefficients is often skewed and not well-approximated by a normal distribution, which is why bootstrapping is generally preferred.", "answer": "$$\\boxed{21.60}$$", "id": "4744347"}]}